Area of Research: Drug Resistance

2022 Grant Recipients

• Jen-Tsan Chi, MD, PhD, Duke University
  Collaborative Research Development Grant
  The Role of Ferroptosis in the Metastatic Ovarian Cancer
• Amrita Salvi, PhD, The University of Illinois at Chicago
  Ann and Sol Schreiber Mentored Investigator Award
  Investigating the mechanism of action of PHY34 in HGSOC

2021 Grant Recipients

• Melanie Weigert, PhD, University of Chicago
  Ann and Sol Schreiber Mentored Investigator Award
  Genome-Wide Profiling of 5-hydroxymethylcytosine on Cell-Free DNA
• Sammy Ferri-Borgogno, PhD, MD Anderson Cancer Center
  Ann and Sol Schreiber Mentored Investigator Award
  Spatially-Resolved Cellular and Transcriptome Analyses of Ovarian Cancer
• Benoît Bragantini, PhD, Mayo Clinic
  Ann and Sol Schreiber Mentored Investigator Award
  Probing Homologous Recombination DNA Repair Factors in Chromatin by cryo-EM
• Ronja Anugwom, PhD, MD Anderson Cancer Center
  Ann and Sol Schreiber Mentored Investigator Award
  Determine Resistance Mechanisms to ATR Inhibition in Ovarian Cancers
• Arun Kanakkanthara, PhD, Mayo Clinic
  Liz Tilberis Early Career Award
  Exploiting a Metabolic Dependency of PARPinhibitor-Resistant Ovarian Cancer
• Liya Ding, PhD, Dana Farber Cancer Institute
  Liz Tilberis Early Career Award
  Targeting Therapeutic Resistance to PARP Inhibition in Ovarian Cancer
• Martin Cannon, PhD, University of Arkansas for Medical Sciences
  Collaborative Research Development Grant
  Understanding and Targeting Myeloid Populations in Ovarian Cancer
• Ivan Ahel, PhD, University of Oxford
  Collaborative Research Development Grant
  Exploiting PARP-Modulating Enzymes in Ovarian Cancer Therapy

2020 Grant Recipients

• Elizabeth Lee, MD, Dana Farber Cancer Institute
  Ann and Sol Schreiber Mentored Investigator Award
  Phase II Trial of Gemcitabine+ATR Inhibitor: Translational Studies
• Sunila Pradeep, PhD, Medical College of Wisconsin
  Liz Tilberis Early Career Award
  Epigenetic Causes of Acquired Resistance of Anti-VEGF Therapy
• Janice Santiago, PhD, MD Anderson Cancer Center
  Ann and Sol Schreiber Mentored Investigator Award
  Crizotinib Improves the Therapeutic Efficacy of Olaparib in Ovarian Cancer
• Morozov Yaroslav, PhD, University of Pennsylvania
  Ann and Sol Schreiber Mentored Investigator Award
  The BRCA1-A as a Determinant of Chemotherapy Response in ATM Mutated Cells

2019 Grant Recipients

• Alexander Cole, PhD, Magee-Womens Research Institute
  Ann and Sol Schreiber Mentored Investigator Award
  Investigating Regulators of Quiescence in Epithelial Ovarian Cancer
• Haineng Xu, PhD, University of Pennsylvania
  Ann and Sol Schreiber Mentored Investigator Award
  A Novel Targeted Therapy for Cyclin E Over Expressing Ovarian Cancers
• Elizabeth Stover, MD, PhD, Dana Farber Cancer Institute
  Liz Tilberis Early Career Award
  Targeting Anti-apoptotic Proteins BCL-XL and MCL-1 in Serous Ovarian Cancer

2018 Grant Recipients

• Damayanti Chakraborty, PhD, Massachusetts General Hospital
  Ann and Sol Schreiber Mentored Investigator Award
  Understanding Epigenetic Regulation of Copy Number Gains in Ovarian Cancer
• Goldie Lui, PhD, Fred Hutchinson Cancer Research Center
  Ann and Sol Schreiber Mentored Investigator Award
  Identifying Novel Targeted Therapies for MYC-driven Ovarian Cancer
• Yinu Wang, PhD, Northwestern University
  Ann and Sol Schreiber Mentored Investigator Award
  Characterization of Chromatin Nanoarchitecture of Ovarian Cancer Stem Cells
• Gordon Mills, MD, PhD, MD Anderson Cancer Center
  Collaborative Research Development Grant
  Rational Combination Therapy in Ovarian Cancer
• Jian Yuan, PhD, Mayo Clinic
  Liz Tilberis Early Career Award
  The Role of BRD9-Rad51 Axis in Chemoresistance in Ovarian Cancer
• David Sabatini, MD, PhD, Whitehead Institute for Biomedical Research
  Collaborative Research Development Grant
  A Personalized Approach to Identify and Target Ovarian Cancer Liabilities

2017 Grant Recipients

• Ilana Chefetz, PhD, University of Michigan
  Liz Tilberis Early Career Award
  Drugs Inducing Necroptotic Cell Death As A New Strategy for High Grade Serous Ovarian Cancer
• Beatrice Rondinelli, PhD, Dana Farber Cancer Institute
  Ann and Sol Schreiber Mentored Investigator Award
  EZH2 Determines PARPi Resistance and Fork Stabilization in Ovarian Tumors
• Sunila Pradeep, PhD, Medical College of Wisconsin
  Liz Tilberis Early Career Award
  Epigenetic Causes of Acquired Resistance to Anti-VEGF Therapy

2016 Grant Recipients

• Jill Madden, PhD, Inc., University of Kansas Medical Center Research Institute
  Ann and Sol Schreiber Mentored Investigator Award
  The Effect of FoxM1 Inhibition on Ovarian Cancer Immunity and Sensitivity
• Beth Y. Karlan, MD, Cedars-Sinai Medical Center
  Collaborative Research Development Grant
  Co-Evolution of Epithelial Ovarian Cancer and Tumor Stroma
• Zihua Gong, MD, PhD, MD Anderson Cancer Center
  Liz Tilberis Early Career Award
  DNA Repair Pathways as Target for Therapy-Resistant Ovarian Cancer

2014 Grant Recipients

• Selvendiran Karuppaiyah, PhD, Ohio State University
  Liz Tilberis Early Career Award
  New Type of Experimental Drug for Ovarian Cancer
• S John Weroha, MD, PhD, Mayo Clinic
  Liz Tilberis Early Career Award
  Ovarian Cancer Surrogates to Study Platinum Resistance
• Nima Aghaeepour, PhD, Stanford University
  Ann and Sol Schreiber Mentored Investigator Award
  Computationally-guided Characterization of Therapy-resistant Ovarian Tumors
• Raphael Ceccaldi, PharmD, PhD, Dana Farber Cancer Institute
  Ann and Sol Schreiber Mentored Investigator Award
  A Bioinformatic Screen Identifies POLQ Overexpression in Ovarian Cancers
• Kyung Hee Noh, PhD, MD Anderson Cancer Center
  Ann and Sol Schreiber Mentored Investigator Award
  Targeting Adaptive Changes to anti-VEGF Therapy in Ovarian Cancer
• Yang Yang, PhD, Yale University
  Ann and Sol Schreiber Mentored Investigator Award
  P53 Aggregation: a New Target to Combat Ovarian Cancer Platinum-Resistance
• Yuyu Yuyu, PhD, Johns Hopkins University School of Medicine
  Ann and Sol Schreiber Mentored Investigator Award
  Targeting Spleen Tyrosine Kinase in Chemoresistant Ovarian Cancer

2013 Grant Recipients

• Elizabeth Swisher, MD, University of Washington
  Collaborative Research Development Grant
  The FA-BRCA Pathway and Response to Platinum and PARP Inhibitors in Ovarian, Tubal and Peritoneal Carcinomas

2012 Grant Recipients

• Ivan Garcia-Bassets, PhD, University of California - San Diego
  Liz Tilberis Early Career Award
  Targeting the Epigenetic Plasticity of the Platinum Response in Drug-resistant Ovarian Cancer Cells
• W. Ruprecht Wiedemeyer, PhD, Cedars-Sinai Medical Center
  Liz Tilberis Early Career Award
  Ovarian Cancer Evolution After Targeted Therapy

2011 Grant Recipients

• Kenneth Nephew, PhD, Indiana University
  Collaborative Research Development Grant
  A New Approach to Treating Recurrent Ovarian Cancer and Newly Diagnosed Disease
• Weiping Zou, MD, PhD, University of Michigan - Ann Arbor
  Collaborative Research Development Grant
  Understanding how Ovarian Cancer Stem Cells Play a Role in Disease Progression and Drug Resistance
• Analisa DiFeo, PhD, moun, Mount Sinai School of Medicine and Case Western Reserve University
  Liz Tilberis Early Career Award
  What is the Relationship Between an miRNA Molecule and Resistance to Chemotherapy?
• Selvendiran Karuppaiyah, PhD, Ohio State University
  Liz Tilberis Early Career Award
  Safe, Targeted, Antitumor Therapeutics (STAT3 Inhibitors) for Ovarian Cancer
• Mary Zhang, MS, PhD, University South Florida
  Liz Tilberis Early Career Award
  Understanding Mechanisms that Lead to Resistance to Platinum-based Treatments

2009 Grant Recipients

• Anil K. Sood, MD, MD Anderson Cancer Center
  Collaborative Research Development Grant
  Novel Treatments for Ovarian Cancer Using siRNAs

2008 Grant Recipients

• Xiaoping He, MD, PhD, Mayo Clinic Rochester
  Ann and Sol Schreiber Mentored Investigator Award
  Understanding the Molecular Pathways to Chemotherapy Resistance in Ovarian Cancer

2006 Grant Recipients

• Aliza Leiser, MD, Yale University
  Ann and Sol Schreiber Mentored Investigator Award
  Clinical Implications of the TLR-4MYD88 Pathway in EOC
• Tsukasa Baba, Duke University
  Ann and Sol Schreiber Mentored Investigator Award
  Using Public Resources to Find New Drugs to Treat Resistant Ovarian Cancer

2003 Grant Recipients

• Karen M. Vasquez, PhD, MD Anderson Cancer Center
  Individual Investigator Award
  Trying to Understand the Mechanism for Cisplatin
• Parameshwar Mahareshti, DVM, University of Alabama - Birmingham
  Individual Investigator Award
  A New Combination Drug Treatment for Ovarian Cancer
• Kuan-Chun Huang, PhD, Brigham and Women’s Hospital
  Ann and Sol Schreiber Mentored Investigator Award
  A Possible New Marker for Drug Resistance of Ovarian Cancer
• Thomas Franke, MD, PhD, Columbia University Medical Center
  Individual Investigator Award
  Finding Molecules to Stop an Abnormal Signaling Pathway in Ovarian Cancer

2002 Grant Recipients

• Fergus Couch, PhD, Mayo Clinic
  Individual Investigator Award
  Finding Genes Associated with Drug Resistance in Ovarian Cancer

2001 Grant Recipients

• Rebecca Liu, MD, University of Michigan
  Liz Tilberis Early Career Award
  Dysfunctional Apoptosome Activation in Ovarian Cancer: Implications for Pathogenesis, Prognosis, and Chemoresistance
• Steven W. Johnson, PhD, University of Pennsylvania
  Individual Investigator Award
  Characterizing Differential Gene Expression of Drug Sensitive and Resistant Ovarian Cancer